SCHEMBL73858

SCHEMBL73858

O=C(O)CN(c1ccccc1)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MLYCD O95822 1/20 0.38
ALDH1A1 P00352 3/20 0.38
CES1 P23141 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
GLA P06280 1/20 0.38
TSHR P16473 1/20 0.38
POLQ O75417 1/20 0.38
KEAP1 Q14145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10659231 0.82 ALDH1A1 (0.42) L3MBTL1NPSR1KMT2AMEN1CYP3A4
Hydrochloric Acid SCHEMBL10674189 0.80 ALDH1A1 (0.41) L3MBTL1NPSR1KMT2AMEN1CYP3A4
SCHEMBL28300016 0.80 MLYCD (0.44) KMT2AMEN1CYP3A4CYP2C9CYP2C19
SCHEMBL2444857 0.80 KMT2A (0.47) L3MBTL1NPSR1KMT2AMEN1CYP3A4
SCHEMBL16858007 0.78 KMT2A (0.46) L3MBTL1NPSR1KMT2AMEN1CYP3A4
SCHEMBL11793707 0.78 CYP2C19 (0.41) L3MBTL1NPSR1TDP1KMT2AMEN1
SCHEMBL9393355 0.77 ALDH1A1 (0.39) L3MBTL1KMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL11792569 0.77 CYP2C19 (0.40) L3MBTL1NPSR1TDP1KMT2AMEN1
SCHEMBL124582 0.74 NPSR1 (0.46) L3MBTL1NPSR1TDP1KMT2AMEN1
SCHEMBL9743711 0.74 NPSR1 (0.46) L3MBTL1NPSR1TDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3334759-B1 LACTOFERRIN FRAGMENT FOR THE USE AS ANTIBACTERIAL AND ANTIVIRAL AGENT FARMAGENS HEALTH CARE SRL (IT) 2019-09-04 EP claimed
US-20030143664-A1 Products of manufacture and processes for peptide synthesis DIVERSA CORPORATION (US) 2003-07-31 US claimed
WO-2003048189-A2 PRODUCTS OF MANUFACTURE AND PROCESSES FOR PEPTIDE SYNTHESIS DIVERSA CORPORATION (US) 2003-06-12 WO claimed
US-12617818-B2 Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them UNIVERSITY OF NORTH TEXAS (US) 2026-05-05 US disclosed
US-20260116948-A1 T CELL RECEPTOR CONSTRUCTS AND USES THEREOF BIONTECH US INC (US) 2026-04-30 US disclosed
US-20260115288-A1 T CELL MANUFACTURING COMPOSITIONS AND METHODS BIONTECH US INC (US) 2026-04-30 US disclosed
US-12606530-B2 Aniline acid anhydride, preparation method therefor, and polyamino acid-grafted chain SOOCHOW UNIVERSITY (CN) 2026-04-21 US disclosed
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 US disclosed
US-20260048116-A1 PROTEIN ANTIGENS AND USES THEREOF BIONTECH US INC (US) 2026-02-19 US disclosed
EP-3365354-B1 PEPTIDES AND PEPTIDOMIMETICS IN COMBINATION WITH T CELL ACTIVATING AND/OR CHECKPOINT INHIBITING AGENTS FOR CANCER TREATMENT CANBAS CO LTD (JP) 2026-02-11 EP disclosed
US-20260034223-A1 BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN NEW YORK UNIVERSITY (US) 2026-02-05 US disclosed
WO-1996040927-A1 ISOSPORA SUIS VACCINE AMBICO, INC. (US) 1996-12-19 WO disclosed
EP-0745095-A1 PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1996-12-04 EP disclosed
US-5508384-A NEUROLEPTIC AGENTS WITH REDUCED SIDE EFFECTS NEW YORK UNIVERSITY (US) 1996-04-16 US disclosed
WO-1995022561-A2 PEPTIDES RECOGNIZED BY MELANOMA-SPECIFIC CYTOTOXIC LYMPHOCYTES, AND USES THEREFOR UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 1995-08-24 WO disclosed
WO-1995020397-A1 PHOSPHACAN, NUCLEIC ACIDS ENCODING THEREOF AND ANTIBODIES THERETO NEW YORK UNIVERSITY (US) 1995-08-03 WO disclosed
WO-1995013828-A1 BENEFICIAL WOUND HEALING APPLICATIONS OF CALRETICULIN AND OTHER HYALURONAN-ASSOCIATED PROTEINS NEW YORK UNIVERSITY (US) 1995-05-26 WO disclosed
WO-1995013291-A1 NEURON-GLIA CELL ADHESION MOLECULE, NG-CAM, IN TREATMENT OF NERVE DAMAGE NEW YORK UNIVERSITY (US) 1995-05-18 WO disclosed
WO-1994003601-A9 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN 1994-03-31 WO disclosed
WO-1994003601-A2 CLONING, EXPRESSION AND USES FOR NEUROCAN AS A CHONDROITIN SULFATE PROTEOGLYCAN NEW YORK UNIVERSITY (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606530-B2 Aniline acid anhydride, preparation method therefor, and polyamino acid-grafted chain BCAT1, GARS1, NGLY1 L3MBTL1 1646/4885NPSR1 1771/4885TDP1 3236/4885
US-20260115288-A1 T CELL MANUFACTURING COMPOSITIONS AND METHODS CD14, CD4, IL2RA L3MBTL1 994/4885NPSR1 945/4885TDP1 3173/4885
US-20260048116-A1 PROTEIN ANTIGENS AND USES THEREOF HLA-DRB1, MICA, TAP2 L3MBTL1 741/4885NPSR1 3972/4885TDP1 3187/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 L3MBTL1 126/4885NPSR1 2252/4885TDP1 3201/4885
US-20260034223-A1 BIOMIMETIC EXTRACELLULAR MATRIX NANOFIBERS ELECTROSPUN WITH CALRETICULIN CALR, ERP44, PDIA4 L3MBTL1 2552/4885NPSR1 2456/4885TDP1 3959/4885
US-12617818-B2 Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them MYLK2, TNNC1, MYOF L3MBTL1 353/4885NPSR1 4457/4885TDP1 2091/4885
US-20260116948-A1 T CELL RECEPTOR CONSTRUCTS AND USES THEREOF MICA, IGSF11, IGLV6-57 L3MBTL1 286/4885NPSR1 3130/4885TDP1 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.